Dr Reddy’s Laboratories has launched levofloxacin tablets (250 mg, 500 mg and 750 mg), a bioequivalent generic version of Levaquin tablets in the US market on June 20, 2011, following the approval by the United States Food & Drug Administration (US FDA) of Dr Reddy’s ANDA for levofloxacin tablets.
The Levaquin brand had US sales of approximately $1.1 billion for the most recent twelve months ending March 2011 according to IMS Health.
Dr Reddy’s levofloxacin tablets 250 mg and 500 mg strengths are available in 50 count bottles and the 750 mg strength is available in 30 count bottles.
Dr Reddy’s Laboratories Ltd. is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Its focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and paediatrics.